Streptococcal Group B Infection Overview

Save information for later
Sign Up

Learn About Streptococcal Group B Infection

What is the definition of Streptococcal Group B Infection?
Group B streptococcus is a blood infection (septicemia) caused by the bacterium, Streptococcus agalactiae, which affects newborn babies. The infection is categorized into two syndromes: 1) early onset (<7 days old) and 2) late onset (7-90 days old). The infection can be caused when the baby moves through the birth canal (early onset), or the baby can become infected after birth through contact with carriers of the bacteria (late onset). Both syndromes can develop into pneumonia and meningitis.
What are the symptoms of Streptococcal Group B Infection?
Symptoms of Group B streptococcal infection in the newborn can include appearing anxious or stressed, blue skin (cyanosis), breathing difficulties, fast or slow heart rate, lethargy, pale, cold skin, poor feeding, and a low or high temperature.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Streptococcal Group B Infection?
The main treatment for Group B streptococcal infection in the newborn is intravenous (IV) antibiotics. Other treatments can include breathing support, intravenous fluids, treatment of shock, correction of blood clotting abnormalities, oxygen therapy, and, in severe cases, the use of a pump to circulate blood through an artificial lung (extracorporeal membrane oxygen).
Who are the top Streptococcal Group B Infection Local Doctors?
Kirsty Le Doare
Elite in Streptococcal Group B Infection
Kirsty Le Doare
Elite in Streptococcal Group B Infection
Kirsty Le Doare
St George's University Of London, 
London, ENG, GB 

Kirsty Le Doare practices in London, United Kingdom. Ms. Le Doare and is rated as an Elite expert by MediFind in the treatment of Streptococcal Group B Infection. Her top areas of expertise are Streptococcal Group B Infection, Neonatal Sepsis, Strep Throat, and Meningitis.

David M. Aronoff
Elite in Streptococcal Group B Infection
Dr. David M. Aronoff
Infectious Disease
Elite in Streptococcal Group B Infection
Dr. David M. Aronoff
Infectious Disease

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Aronoff is an Infectious Disease provider in Indianapolis, Indiana. Dr. Aronoff and is rated as an Elite provider by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Streptococcal Group B Infection, Strep Throat, Sepsis, and Pneumonia. Dr. Aronoff is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Shabir A. Madhi
Elite in Streptococcal Group B Infection
Shabir A. Madhi
Elite in Streptococcal Group B Infection
Shabir A. Madhi
Johannesburg, GT, ZA 

Shabir Madhi practices in Johannesburg, South Africa. Mr. Madhi and is rated as an Elite expert by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Streptococcal Group B Infection, Strep Throat, Parainfluenza, and Pneumonia.

View All Doctors
What are the latest Streptococcal Group B Infection Clinical Trials?
A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy
A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy
Enrollment Status: Recruiting
Publish Date: June 17, 2025
Intervention Type: Biological
Study Phase: Phase 2/Phase 3

Summary: The main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccination with GBS-NN/NN2 in all participants.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.
A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.
Enrollment Status: Recruiting
Publish Date: January 17, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).

View All Clinical Trials